FY2025 · ended Dec 31, 2025 · Revenue $5.14B, +21.2% YoY · Filed Feb 10, 2026
Incyte Corporation (INCY) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $5.1 billion and net income of $1.3 billion. As of Sep 30, 2026 it held $3.3 billion in cash and investments and $37.4 million in total debt.
Revenue (TTM)
$6.01B
+24.9% vs year-ago TTM
Net income (TTM)
$403.41M
-66.1% vs year-ago TTM
Operating cash flow (TTM)
$744.99M
-40.5% vs year-ago TTM
Free cash flow
$892.11M
+56.9% vs prior year
EPS (TTM)
$1.94
-67.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
199.01M
+2.8% vs prior year
Net cash
$3.24B
as of Sep 30, 2026
Operating margin
10.4%
FY 2026
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- INCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Large accelerated filer
- SEC CIK
- 879169
- Former names
- INCYTE INC (until Mar 28, 2003); INCYTE GENOMICS INC (until Feb 25, 2003); INCYTE PHARMACEUTICALS INC (until Apr 18, 2000)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.1B | $4.2B | $3.7B | $3.4B | $3.0B |
| Operating income | $1.5B | $61.4M | $620.5M | $579.4M | $585.8M |
| Net income | $1.3B | $32.6M | $597.6M | $340.7M | $948.6M |
| Diluted EPS | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 |
| Operating cash flow | $1.4B | $335.3M | $496.5M | $969.9M | $749.5M |
| Free cash flow | — | — | — | $892.1M | $568.5M |
| Total assets | $7.0B | $5.4B | $6.8B | $5.8B | $4.9B |
| Total liabilities | $1.8B | $2.0B | $1.6B | $1.5B | $1.2B |
| Stockholders' equity | $5.2B | $3.4B | $5.2B | $4.4B | $3.8B |
| Cash and investments | $3.1B | $1.7B | $3.8B | $3.4B | $2.6B |
| Total debt | $54.9M | $60.3M | $52.6M | $55.6M | $60.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Aug 31, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Jul 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Other events
|
Jul 6, 2026 | Jul 6, 2026 |
All 1002 Incyte Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.